Tim Witney
Chief Scientific Officer Nuclide Therapeutics
Seminars
Wednesday 12th November 2025
Targeting ALDH1A1 for the Identification & Treatment of Therapy Resistant Cancers
12:00 pm
- Targeting the cancer stem cell marker – AzLDH1A1
- Identifying refractory disease with our first-in-class theranostic, [18F]NTx-10
- Treating therapy-resistant non-small cell lung cancer with [131I] NTx-11
